NICE recommends interim funding for GSK’s Zejula in ovarian cancerWomen with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding Share XNICE recommends interim funding for GSK’s Zejula in ovarian cancerhttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-gsks-zejula-in-ovarian-cancer/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerNICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in Share XUnconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerhttps://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
CLL patients in England to get AZ’s Calquence after okay from NICENHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic Share XCLL patients in England to get AZ’s Calquence after okay from NICEhttps://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/
iRhythm digital heart monitoring service backed by NICEA heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a Share XiRhythm digital heart monitoring service backed by NICEhttps://pharmaphorum.com/news/irhythm-digital-heart-monitoring-service-backed-by-nice/
NICE says yes to Braftovi combination for colorectal cancerTwo months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has Share XNICE says yes to Braftovi combination for colorectal cancerhttps://pharmaphorum.com/news/nice-says-yes-to-braftovi-combination-for-colorectal-cancer/
NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/
Vertex Pharma’s vision for reimbursement innovationAs regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s Share XVertex Pharma’s vision for reimbursement innovationhttps://pharmaphorum.com/views-analysis-market-access/vertex-pharmas-vision-for-reimbursement-innovation/
